Algernon Value Proposition

About our
Company

Who we are
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Algernon’s key compounds were identified using a drug repurposing strategy.
Our Process
Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

The Algernon business model is to advance known, safe and already approved drugs for new disease indications.

The Company is developing drugs for the following 3 major disease areas:
Non-alcoholic Steatohepatitis (NASH)
Chronic Kidney Disease (“CKD”)
Inflammatory Bowel Disease (IBD)

Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 3 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
Non–alcoholic Steatohepatitis
More about NASH
Chronic Kidney Disease
More about CKD
Inflammatory Bowel Disease
More about IBD